Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 4/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26206102 | 0.90 | MAPT (0.39) | PPARGMAPTALOX5ACACB | |
| SCHEMBL26206481 | 0.88 | TSHR (0.44) | S1PR1S1PR2S1PR3MAPTRXFP1 | |
| SCHEMBL26206475 | 0.87 | S1PR2 (0.37) | S1PR1PPARGS1PR2S1PR3MAPT | |
| SCHEMBL26206459 | 0.82 | FFAR1 (0.47) | S1PR1S1PR2S1PR3MAPTRXFP1 | |
| SCHEMBL22525552 | 0.81 | AAK1 (0.45) | ACACB | |
| SCHEMBL26206369 | 0.81 | FFAR4 (0.39) | PPARGFFAR1FFAR4 | |
| SCHEMBL26206374 | 0.81 | PPARA (0.51) | PPARGMAPTRXFP1FFAR1 | |
| SCHEMBL26206373 | 0.80 | TBXA2R (0.37) | S1PR1MAPTRXFP1LTB4RFFAR4 | |
| SCHEMBL25123141 | 0.80 | PPARG (0.38) | PPARGACACB | |
| SCHEMBL26205635 | 0.77 | TSHR (0.42) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | S1PR1 3138/4885PPARG 1830/4885S1PR2 3085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.